Publications by authors named "J A Tomlinson"
Introduction: Cardiovascular disease is the commonest cause of death in Turner syndrome (TS) for which, arterial hypertension has a direct influence and is a key modifiable risk factor.
Objective: To investigate the prevalence and patterns of hypertension diagnosis and management in adult patients with TS who are registered in a large international multicentre database (TS-HTN study).
Methods: Retrospective multi-centre observational study of patients aged ≥18 years, included in the I-TS (International-TS) registry (2020-2022) utilising registry and participating centre collected data.
Article Synopsis
- Evidence-based bundles for inserting and maintaining central lines significantly lower the rates of CLABSI in ICUs.
- Researchers examined how well these prevention programs were adopted and followed in ICUs across a large network of Canadian hospitals.
- The study focused on the relationship between compliance with these bundles and actual CLABSI rates.
Objectives: To determine the clinical outcomes of patients with immunoglobulin 4-related disease (IgG4-RD) treated with a defined B cell depletion protocol using rituximab.
Methods: Patients were included if they had (1) an IgG4-RD diagnosis at Imperial College Healthcare NHS Trust between February 2017 and October 2022, and (2) >9 months of follow-up data available following the first rituximab dose. The rituximab protocol targeted B cell depletion to < 10 cells/microliter for a maintenance period of two years.
Background: While many clinical computed tomography (CT) protocols use helical scanning, the traditional method for measuring the volume CT Dose Index (CTDI) requires modifying the helical protocol to perform a single axial rotation. This modification can present challenges and mismatched settings across various scanner models.
Purpose: This study investigates the generalizability of a helical methodology for estimating CTDI across a diverse range of participants, CT scanner models, and protocol parameters.
Introduction: In people living with chronic obstructive pulmonary disease (COPD), we aimed to estimate: (1) the prevalence of glucocorticoid-induced hyperglycaemia (GIH); (2) whether the prevalence of GIH varies by age, baseline diabetes status, treatment duration, ascertainment of glycaemia, definition of hyperglycaemia, study design and year of publication; and (3) the relative risk (RR) of new-onset hyperglycaemia in exposed vs non-exposed to systemic glucocorticoids.
Methods: We searched electronic databases until 9 November 2023 for randomised controlled trials and observational studies including adults diagnosed with COPD, with or without diabetes at baseline, using systemic glucocorticoids equivalent to prednisolone ≥5 mg/day for ≥3 days if exposed. Hyperglycaemia was defined as a blood glucose above a study-specific cut-off.